Diabetes

September 4, 2019
Published by admin_auro at September 4, 2019
Categories

New Mechanistic and functional  insights into how Teneligliptin mitigates complications of diabetes and obesity:  Teneligliptin (brand names: Tenelin), a DPP4 (dipeptidyl peptidase 4 ) inhibitor,  augments the expression of FGF19 and FGF1,  attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates diabetes mellitus, via down regulation of its target gene, 4/September/2019, 9.30 am

Introduction: What they say  A study from Diabetes and Obesity Center of Excellence, Department of Medicine, University of Washington, Seattle, Washington, USA shows that Central injection […]
Do you like it?0
Read more
August 25, 2019
Published by admin_auro at August 25, 2019
Categories

New Mechanistic and functional insights into how Vildagliptin mitigates complications of diabetes and obesity:  Vildagliptin/LAF237 (brand names: Galvus/Vildagluse/Gliptus), a DPP4 (dipeptidyl peptidase 4 ) inhibitor,  augments the expression of FGF19 and FGF1,  attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates diabetes mellitus, via down regulation of its target gene, 25/August/2019, 11.49 pm

Introduction: What they say  A study from Diabetes and Obesity Center of Excellence, Department of Medicine, University of Washington, Seattle, Washington, USA shows that Central injection […]
Do you like it?0
Read more
August 23, 2019
Published by admin_auro at August 23, 2019
Categories

The Mechanistic basis of how Liraglutide mitigates complications of diabetes and obesity:  Liraglutide (trade name: Victoza, Saxenda), a Glucagon-like peptide-1  (GLP-1) receptor agonist,  augments the expression of FGF19 and FGF1,  attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates diabetes mellitus, via down regulation of its target gene, 24/August/2019, 12.27 am

Introduction: What they say  A study from Diabetes and Obesity Center of Excellence, Department of Medicine, University of Washington, Seattle, Washington, USA shows that Central injection […]
Do you like it?0
Read more
August 19, 2019
Published by admin_auro at August 19, 2019
Categories

The Mechanistic basis of how Dulaglutide (Trulicity) once-weekly injection mitigates complications of diabetes and obesity: Dulaglutide (trade name: Trulicity), a Glucagon-like peptide-1  (GLP-1) receptor agonist,  augments the expression of FGF19 and FGF1,  attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates diabetes mellitus, via down regulation of its target gene, 19/August/2019, 1.53 pm

Introduction: What they say  A study from Diabetes and Obesity Center of Excellence, Department of Medicine, University of Washington, Seattle, Washington, USA shows that Central injection […]
Do you like it?0
Read more
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112
Next page